JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma
SHANGHAI,Jan. 10,2025--JW Therapeutics (HKEx: 2126),an independentandinnovative biotechnology company focused on developing,manufacturing and commercializing cell immunotherapy products,announced that